Madam Therapeutics

New strategies in the treatment of infections are warranted, as antibiotic resistance (antimicrobial resistance, AMR) is emerging. This resistance will increase over the coming years and decades because of the excessive use of traditional antibiotics in humans and animals. Currently annual deaths are contributed to antimicrobial resistance, but estimations tell us that by 2050 AMR will be responsible for about 10 million deaths annually, surpassing cancer and diabetes in annual fatalities. Globally AMR is viewed more and more as a significant public health threat. Madam Therapeutics develops next-generation antibiotics for the treatment of multi-drug resistant (MDR) infectious diseases • The company has developed a breakthrough platform technology of novel peptide antibiotics with a broad activity against a wide spectrum of bacteria • Unique MoA based on natural defense peptides in humans and rapid eradication of multi-drug resistant bacteria • Anti-biofilm capabilities and highly robust against resistancy development • Strong IP: 2 patent families covering 10*E26 configurations • Efficacy and safety demonstrated preclinically for multiple MDR bacteria • Safety confirmed in animals • Broad applicability in high value markets • Suitable for human and veterinary applications • Applicable to broad and multi-billion $ markets (implant infections, MRSA, urinary tract infections, Lyme disease, burn infections, sepsis, respiratory.) • Potential for premium pricing: Clear health economic benefit allowing 1st line use at introduction and high differentiation to competitors